Cancer Network

11/11/2025

Data from the phase 2 INTERACT-ION trial support further investigation of the potential synergistic effect of ezabenlimab plus adaptive chemoradiotherapy.

https://hubs.li/Q03Sw8wz0

Data from the phase 2 INTERACT-ION trial support further investigation of the potential synergistic effect of ezabenlimab plus adaptive chemoradiotherapy.

11/11/2025

The trial will evaluate lacutamab in patients with Sézary syndrome and mycosis fungoides, and developers aims to launch the trial in the first half of 2026.

https://hubs.li/Q03Sw4zf0

11/10/2025

Cancer care thrives when every discipline collaborates.

Join oncologists, nurses, pharmacists, and researchers at the 43rd Annual Chemotherapy Foundation Symposium (CFS®) this week in New York City.

Explore the breakthroughs shaping multidisciplinary care from biomarker testing and immunotherapy to toxicity management and supportive care.

Your role is vital in advancing patient outcomes.

Watch the preview and register now: https://hubs.li/Q03Swn7N0

11/10/2025

How can Scout AI affect oncology decision making?

Read here to find out: https://hubs.li/Q03SgWxh0

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

11/10/2025

At , Aditya Bardia, MD, MPH, FASCO, spoke about the future direction of ADCs. Among those topics was the strain that the toxicity may place upon patients.

https://hubs.li/Q03Sh1dQ0

| UCLA Jonsson Comprehensive Cancer Center

11/10/2025

The FDA has issued final approval for an abbreviated new drug application for generic dasatinib tablets at 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg in various adult CML and ALL populations, as well as a pediatric CML population.

Read here: https://hubs.li/Q03SgXQb0

11/10/2025

Palazestrant plus ribociclib led to a median PFS of 15.5 months in all patients with ER+/HER2– breast cancer, and 12.2 months for those with prior receipt of CDK4/6 inhibitors plus endocrine therapy.

https://hubs.li/Q03Sh1fm0

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable to prior reports of each individual agent.

11/09/2025

🚨 You know this already, but there's a new top 5! 🚨

1. https://hubs.li/Q03SgVWr0
2. https://hubs.li/Q03SgXP-0
3. https://hubs.li/Q03SgXrC0
4. https://hubs.li/Q03SgWwJ0
5. https://hubs.li/Q03SgVz80

11/09/2025

Cancer cachexia poses a profound clinical challenge in oncology, negatively impacting patient outcomes, tolerance to treatment, and overall quality of life.

Read Vickie Baracos, PhD's thoughts here: https://hubs.li/Q03SgQtF0

Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.

11/08/2025

Zurletrectinib was tolerable and showed promising antitumor activity in pediatric and adolescent patients with NTRK/ROS1-altered solid tumors.

https://hubs.li/Q03SgQZj0

No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.

11/08/2025

Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.

https://hubs.li/Q03Sgyxd0

Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.

11/07/2025

Adding radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver, according to Michael C. Soulen, MD.

Listen here: https://hubs.li/Q03S5nHX0

| Penn Medicine - Abramson Cancer Center

The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.